JULIET: Overall population
Efficacy1,2
PFS1
OS at
2 years
%
ORR
%
CR
%
| Safety2 | |
|---|---|
| CRSGrade ≥3 | % |
| ICANSGrade ≥3 | % |
- References: 1. Jaeger U et al. Poster presented at the 2021 Transplantation and Cellular Therapy Annual Meeting, held virtually on 8–12 February 2021. Poster 212.
- 2. Schuster SJ et al. Lancet Oncol 2021;22(10):1403–1415.
Efficacy1
PFS by lymphodepletion regimen1
- Reference: 1. Jaeger U et al. Poster presented at the 2021 Transplantation and Cellular Therapy Annual Meeting, held virtually on 8–12 February 2021.
Data collection
Jul 2015–Nov 2017 enrolment
Australia, Austria, Canada, France, Germany, Italy, Japan, the Netherlands, Norway, and the US
Median follow-up
months
(data cut-off Feb 2020)
No. of patients infused with tisa-cel
| Median age (range) years1,2Patients ≥65 years | 56 (22–76)23% |
| Gender (male)2 | ~65% |
| ECOG ≥2 | 0 |
| IPI (≥2 at study entry) | 73% |
| HG lymphoma(double or triple hit) | 17% |
| DLBCL | 80% |
| Transformed lymphoma | 18% |
| Comorbidities | NR |
| LDH elevated | 52% |
| Prior therapies, median (IQR)≥3 lines | 3 (2-3)51% |
| Primary refractoryRefractory to last lineRelapsed | NR55%45% |
| Prior SCT autoAllo | 49%0 |
| Bridging therapy | 90% |
- References: 1. Schuster SJ et al. Lancet Oncol 2021;22(10):1403–1415.
- 2. Schuster SJ et al. N Engl J Med. 2019;380(1):45–56.
90%
(104/115) of patients in JULIET received bridging therapy (BT)*
53%
of patients who received BT had ECOG PS 0 vs.
90%
of those who did not receive BT
| Efficacy | ||
|---|---|---|
| BT | No BT | |
| PFSat 12 months | 32% | 61% |
| ORR | 49% | 82% |
| Safety | ||
|---|---|---|
| BT | No BT | |
| CRSGrade 3Grade 4 | 14%10% | 9%0% |
| ICANSGrade 3Grade 4 | 7%5% | 9%0% |
Although the sample size is small (n=11), patients not requiring BT appeared to have less aggressive disease, achieved higher response rates and had no grade 4 CRS or neurological events
*90 patients received systemic therapy alone, 13 received systemic therapy in combination with radiation therapy and 1 patient received radiation therapy alone
- Reference: 1. Andreadis C et al. American Society of Hematology Annual Meeting, 7–10 December 2019, Orlando, FL. Poster 2883.
Patient
summary
Your patient summary will be shown here as you save you patient selections
This is where your patient summary will be shown. If you would like more tailored data, create a patient profile
Start a patient profile3L+ DLBCL PATIENT
Patient profile
- Incomplete
Treatment history
- Incomplete
Treatment choice
- Incomplete